Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study

• Päätekijät: Charlotte Bellier (Tekijä), Laurence Gladieff (Tekijä), Fanny Le Du (Tekijä), Dominique Berton (Tekijä), Charlotte Bonnard (Tekijä), Delphine Suau (Tekijä), Anne-Céline Richard (Tekijä), Ophélie Brenner (Tekijä), Amir Lahouegue (Tekijä), Gilles Freyer (Tekijä), Anne Floquet (Tekijä), Sophie Frank (Tekijä), Maria Kfoury (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Adis, Springer Healthcare, 2023-01-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Abstract Background Olaparib, a poly(ADP-ribose) polymerase inhibitor, was approved by the European Commission in June 2019, following the results of the SOLO-1/GOG 3004 trial as maintenance monotherapy in adult patients with BRCA-mutated epithelial ovarian cancer. Objective This study aimed to prov...